P21 represents a novel nootropic peptide aimed at supporting neurogenesis, synaptic plasticity, and long-term brain health. Derived from the ciliary neurotrophic factor (CNTF) system, P21 elevates BDNF le...
P21 represents a novel nootropic peptide aimed at supporting neurogenesis, synaptic plasticity, and long-term brain health. Derived from the ciliary neurotrophic factor (CNTF) system, P21 elevates BDNF levels, modulates CREB signaling, and helps counteract amyloid and tau pathologies in preclinical models. Studies indicate that this peptide can improve learning and memory, increase resistance to neuroinflammation and oxidative stress, and facilitate structural reorganization in key brain regions including the hippocampus.
P21 increases Brain-Derived Neurotrophic Factor (BDNF) levels, activates CREB-dependent pathways promoting hippocampal neurogenesis and synapse remodeling.
Administration Method:
Intranasal route is preferred for targeted delivery into the central nervous system; subcutaneous injection serves as a systemic alternative.
Typical Dosage Ranges Investigated:
Conservative Approach: 250–500 mcg once daily with initial evaluation lasting 2–4 weeks.
Standard Protocol: 500–750 mcg once daily over 8–12 week course duration.
Advanced Regimen: 750–1000 mcg once daily up to 8–12 weeks followed by reassessment.
Course Duration: taken daily at the same time; effects accumulate gradually over several weeks rather than instantaneously.
